"LogProstyle†), a leading real estate renovation and resale, development, hotel and restaurant management company, today announced that it will process a refund of Japanese withholding income tax in connection with the cash dividend described below, as previously disclosed by the Company on July 7, 2025. Cash Dividend Parameters: Record Date: July 7, 2025 Payment Date: August 5, 2025 Dividend per Share: US$0.023 Ca. TOKYO--(BUSINESS WIRE)--LogProstyle Inc. (NYSE American: LGPS) (the "Company†or ...

Core Insights - Sai Life Sciences Limited released its Sustainability Report for 2024–25, focusing on "Driving climate action, deepening stakeholder trust" and aligning with GRI and SASB standards [1][2] Sustainability Strategy - The company's sustainability strategy is based on nine strategic pillars: water stewardship, climate action, circularity, biodiversity, sustainable procurement, human capital, governance and ethics, community engagement, and customer co-creation [2][3] - These pillars integrate sustainability into all operational stages, aligning with business objectives and stakeholder expectations [2] Sustainable Development Goals - Sai Life Sciences has defined Sustainable Development Goals (SDGs) to meet its sustainability commitments by March 31, 2027, with ongoing progress in greenhouse gas reduction and renewable energy usage [3][4] - The API manufacturing unit in Bidar is powered by 96% renewable energy, and the company has reduced specific water consumption across its facilities [3] Community Impact - The company exceeded its commitment to provide education and livelihood opportunities for 8,000 individuals from underprivileged communities, demonstrating significant community impact [3] Workforce Diversity - The organization has seen steady growth in diversity, with women representing 14% of the workforce [3] Long-term Vision - The 2024–25 Sustainability Report reflects the company's long-term view, emphasizing science, responsibility, and collaboration as central to its growth ambitions [4]

Core Insights - WuXi AppTec has been awarded the 2025 Global Company of the Year Award in the CRDMO industry by Frost & Sullivan, marking the ninth consecutive year of receiving this honor, which highlights the company's achievements in innovation and operational excellence [1][4] Company Overview - WuXi AppTec operates as a leading global pharmaceutical CRDMO, providing integrated, end-to-end services that drive scientific and technological advancement, enabling faster drug development and delivery of transformative therapies [2][5] - The company has established a robust foundation of scientific capability, quality, and customer-focused agility through a forward-looking growth strategy, which includes continuous investment in next-generation technologies such as complex peptides, oligonucleotides, and novel conjugates [3][5] Strategic Partnerships and Market Position - The integrated CRDMO model of WuXi AppTec eliminates handoffs between development stages, supporting continuity, quality, and compliance across the value chain, which helps clients reduce risk and improve efficiency [3][4] - The company serves a diverse range of clients, from emerging biotech firms to pharmaceutical multinationals, ensuring fast access to specialized expertise and a global infrastructure [3][5] Leadership and Future Focus - Dr. Ge Li, Chairman and CEO of WuXi AppTec, emphasized the commitment of the global teams to enable customers to advance medicines through the integrated CRDMO platform, with a focus on expanding global capabilities and capacity [4] - Frost & Sullivan's recognition is based on outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning [4]

Core Insights - Sprott Critical Materials ETF (SETM) has reached $100 million in assets under management as of September 23, 2025, and is the only ETF providing pure-play exposure to critical materials and mining equities essential for energy generation, transmission, and storage [1][2]. Investment Opportunity - The growing gap between supply and demand for materials essential to electrification is prompting nations to focus on energy security and resource nationalism, creating investment opportunities in the critical materials sector [2]. - SETM's index methodology ensures that only companies with a majority of their business operations related to critical materials are included, focusing on those involved in mining, exploration, development, production, recycling, refining, or smelting [2]. ETF Suite Overview - SETM is part of a suite of seven Sprott Critical Materials ETFs, which combine the benefits of ETFs with exposure to various critical materials and their miners [3]. - The suite includes ETFs focused on uranium, copper, lithium, nickel, and other critical materials, each designed to track specific indices related to their respective sectors [3][4]. Company Background - Sprott Asset Management USA, Inc. is a global asset manager specializing in precious metals and critical materials investments, with a focus on providing in-depth knowledge and experience in the sector [6].

Core Insights - The company is on track to achieve platform adjusted EBITDA profitability in the second half of 2025 [1][3] - The second quarter results reflect a positive step towards this goal, with a focus on hospitality, multifamily, and multi-tenant industrial real estate [3][6] - Recent legislative changes, specifically the passage of the BBB, have made the opportunity zone program permanent, benefiting the company's investment strategies [3] Financial Highlights - Platform revenue for Q2 2025 was $4.1 million, slightly down from $4.2 million in Q2 2024 [6] - The platform net loss was $4.9 million, or $3.87 per diluted share, compared to a net loss of $4.6 million, or $4.25 per diluted share in the prior year [6] - Platform adjusted EBITDA loss improved to $0.1 million from a loss of $2.5 million in the same quarter last year [6] Business Updates - Key milestones include the approval of the Canyon Village redevelopment project, which will convert a distressed office building into a 376-unit rental multifamily residential building [7] - The joint venture project, PURE Pickleball & Padel™, received design review approval, positioning it for a building permit [7] - A successful refinancing of $22.5 million for the Doubletree by Hilton Hotel in Tucson was completed [7] Consolidated Financial Results - Total consolidated revenue decreased to $5.1 million from $8.2 million, primarily due to the deconsolidation of several entities in 2024 [7] - Consolidated net loss attributable to Caliber was $5.3 million, or $4.15 per diluted share, compared to a net loss of $4.7 million, or $4.34 per diluted share in the previous year [7] - Consolidated adjusted EBITDA showed improvement, reaching $0.1 million compared to a loss of $1.0 million in Q2 2024 [7] Assets Under Management - As of June 30, 2025, the fair value of assets under management (AUM) was $803.2 million, up from $794.9 million at the end of 2024 [23][24] - The company reported a total managed capital of $498.6 million, reflecting an increase from $492.5 million at the end of 2024 [25][26]

Core Insights - WuXi Biologics has achieved fully automated continuous drug substance production at pilot scale using its WuXiUP™ platform, enhancing efficiency and flexibility for clients [1][4][6] Production Efficiency - The WuXiUP™ platform allows for non-stop 24/7 operation, minimizing manual intervention and reducing quality risks, leading to enhanced manufacturing efficiency [2] - In upstream processes, WuXiUP™ has demonstrated a total output exceeding 110 g/L over 24 days of continuous cell culture, with a peak daily yield of 7.6 g/L [2] - The downstream purification process utilizes a two-step, high-efficiency membrane chromatography system, resulting in a 5- to 10-fold increase in productivity compared to traditional methods [2][6] Quality Control - WuXiUP™ employs advanced Process Analytical Technology (PAT) for real-time monitoring of critical parameters, significantly improving manufacturing procedure control [3] - The integration of automated closed-loop control systems with PAT allows for intelligent diversion of out-of-spec samples, enhancing overall quality control [3] Technological Advancements - The platform is designed to manufacture a variety of pharmaceutical proteins, achieving 5–20 times higher productivity compared to traditional processes [5] - Notably, when scaling to 1,000–2,000 L using single-use bioreactors, WuXiUP™ achieves productivity levels comparable to traditional 10,000–20,000 L stainless steel bioreactors [6] Regulatory Success - The WuXiUP™ platform has facilitated one molecule to receive Biologics License Application (BLA) approval and 11 others to receive Investigational New Drug (IND) approvals [6]

Core Viewpoint - WuXi Biologics has launched the WuXia293Stable platform, enhancing the development and manufacturing of complex biologics with high titers, stability, and quality [1][6]. Group 1: Platform Features - WuXia293Stable is designed for innovative, difficult-to-express molecules, demonstrating high titers of up to 5.0 g/L for monoclonal antibodies while improving purity [4][10]. - The platform maintains stable expression and consistent quality during long-term cell passages, enabling scalable clinical and commercial manufacturing at 2000L for fed-batch and 1000L for perfusion [4][10]. - It offers a comprehensive suite of services, including cell bank testing and viral clearance validation, as part of its one-stop CMC solution [4]. Group 2: Comparison with CHO Cells - Traditionally, CHO cells have been used for recombinant protein expression but may face challenges with complex modalities, leading to low titer levels and truncation issues [2]. - HEK293 cells, utilized in WuXia293Stable, can alleviate truncation issues while maintaining high titer levels, making them more suitable for complex molecules [2]. Group 3: Company Commitment and Vision - The launch of WuXia293Stable reinforces WuXi Biologics' commitment to technological innovation and the vision that every biologic can be made [6]. - The WuXia™ platform family, which includes WuXia293Stable, has generated over 1000 cell lines for various therapeutic applications, showcasing its proven track record [7][8].

Core Insights - Caliber is focusing on sustainable profitability and has narrowed its strategy to emphasize hospitality, multifamily, and multi-tenant industrial real estate [3][5] - The company reported a platform revenue of $3.5 million for Q1 2025, down from $4.7 million in Q1 2024, with a platform net loss of $4.1 million compared to a loss of $3.6 million in the prior year [7][15] - Recent partnerships and projects, including a collaboration with Hyatt and the approval of a redevelopment project, are expected to enhance future performance [4][8] Financial Highlights - Platform revenue decreased to $3.5 million in Q1 2025 from $4.7 million in Q1 2024, with asset management revenue also at $3.5 million [7][22] - The platform net loss was $4.1 million, or $3.59 per diluted share, compared to a net loss of $3.6 million, or $3.30 per diluted share in the previous year [7][15] - Total consolidated revenue fell to $7.3 million from $23.0 million, primarily due to the deconsolidation of certain entities [15][29] Business Developments - Caliber announced a partnership with Hyatt to develop 15 new Hyatt Studios hotels across several states, which is seen as a strategic advantage [4][8] - The company launched a 1031 Exchange Program aimed at providing tax-deferral benefits for real estate investors [8] - The Phoenix City Council approved Caliber's Canyon Village redevelopment project, converting a distressed office building into a multifamily residential building [8] Asset Management Performance - The fair value of assets under management (AUM) increased to $830.8 million as of March 31, 2025, up from $794.9 million at the end of 2024 [24][28] - The company reported a total asset management revenue of $3.5 million for Q1 2025, down from $4.6 million in Q1 2024 [22][31] - The platform adjusted EBITDA loss was $1.4 million, an improvement from a loss of $1.7 million in the previous year [7][48]

Core Viewpoint - Caliber (NASDAQ: CWD) will release its first quarter 2025 financial results on May 15, 2025, and will host a conference call to discuss these results [1][2]. Group 1: Financial Results Announcement - Caliber will announce its Q1 2025 financial results after market close on May 15, 2025 [1]. - A webcast/conference call is scheduled for the same day at 5:00 pm ET for interested parties to discuss the results [1]. Group 2: Accessing the Earnings Call - Investors can join the live earnings call by dialing (800) 715-9871 for domestic calls or (646) 307-1963 for international calls, using conference ID 8746759 [2]. - The call can also be accessed online via Caliber's investor relations page [2]. Group 3: Company Overview - Caliber manages over $2.9 billion in assets and has a 16-year track record in real estate management and development [4]. - The company specializes in hospitality, multi-family residential, and multi-tenant industrial sectors, aiming to generate profits in all market conditions [4]. - Caliber's competitive advantage lies in investing in overlooked projects and geographies, supported by an in-house shared services group for better control and visibility [4].